Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma

P. Alberto, M. Rozencweig, M. Clavel, P. Siegenthaler, F. Cavalli, S. Gundersen, U. Bruntsch, J. Renard, H. Pinedo

Research output: Contribution to journalArticle

Abstract

Forty-two patients with malignant melanoma were treated with doxifluridine, 4000 mg/m2 daily ×5, repeated every 3 weeks. The daily dose was reduced to 3000 mg/m2 in patients who had experienced severe myelosuppression with prior chemotherapy. A total of 35 patients were evaluable for response, and 25 of these received two or more courses. Two responses were observed. Toxicity mainly took the form of nausea, vomiting, stomatitis, dizziness, ataxia, and fatigue. Mild leukopenia was frequent (43%). Nadir counts 9/l leukocytes or 50×109/l platelets were seen in 7% and 2% of the courses respectively. Doxifluridine has no useful activity against malignant melanoma.

Original languageEnglish (US)
Pages (from-to)78-79
Number of pages2
JournalCancer Chemotherapy and Pharmacology
Volume16
Issue number1
DOIs
StatePublished - Jan 1986
Externally publishedYes

Fingerprint

Melanoma
Chemotherapy
Platelets
Toxicity
Stomatitis
Leukopenia
Dizziness
Fatigue of materials
Ataxia
Nausea
Vomiting
Fatigue
Leukocytes
Blood Platelets
Drug Therapy
doxifluridine

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Alberto, P., Rozencweig, M., Clavel, M., Siegenthaler, P., Cavalli, F., Gundersen, S., ... Pinedo, H. (1986). Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma. Cancer Chemotherapy and Pharmacology, 16(1), 78-79. https://doi.org/10.1007/BF00255292

Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma. / Alberto, P.; Rozencweig, M.; Clavel, M.; Siegenthaler, P.; Cavalli, F.; Gundersen, S.; Bruntsch, U.; Renard, J.; Pinedo, H.

In: Cancer Chemotherapy and Pharmacology, Vol. 16, No. 1, 01.1986, p. 78-79.

Research output: Contribution to journalArticle

Alberto, P, Rozencweig, M, Clavel, M, Siegenthaler, P, Cavalli, F, Gundersen, S, Bruntsch, U, Renard, J & Pinedo, H 1986, 'Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma', Cancer Chemotherapy and Pharmacology, vol. 16, no. 1, pp. 78-79. https://doi.org/10.1007/BF00255292
Alberto, P. ; Rozencweig, M. ; Clavel, M. ; Siegenthaler, P. ; Cavalli, F. ; Gundersen, S. ; Bruntsch, U. ; Renard, J. ; Pinedo, H. / Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma. In: Cancer Chemotherapy and Pharmacology. 1986 ; Vol. 16, No. 1. pp. 78-79.
@article{5a3088ec7d414b2098a2093ee15016b3,
title = "Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma",
abstract = "Forty-two patients with malignant melanoma were treated with doxifluridine, 4000 mg/m2 daily ×5, repeated every 3 weeks. The daily dose was reduced to 3000 mg/m2 in patients who had experienced severe myelosuppression with prior chemotherapy. A total of 35 patients were evaluable for response, and 25 of these received two or more courses. Two responses were observed. Toxicity mainly took the form of nausea, vomiting, stomatitis, dizziness, ataxia, and fatigue. Mild leukopenia was frequent (43{\%}). Nadir counts 9/l leukocytes or 50×109/l platelets were seen in 7{\%} and 2{\%} of the courses respectively. Doxifluridine has no useful activity against malignant melanoma.",
author = "P. Alberto and M. Rozencweig and M. Clavel and P. Siegenthaler and F. Cavalli and S. Gundersen and U. Bruntsch and J. Renard and H. Pinedo",
year = "1986",
month = "1",
doi = "10.1007/BF00255292",
language = "English (US)",
volume = "16",
pages = "78--79",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma

AU - Alberto, P.

AU - Rozencweig, M.

AU - Clavel, M.

AU - Siegenthaler, P.

AU - Cavalli, F.

AU - Gundersen, S.

AU - Bruntsch, U.

AU - Renard, J.

AU - Pinedo, H.

PY - 1986/1

Y1 - 1986/1

N2 - Forty-two patients with malignant melanoma were treated with doxifluridine, 4000 mg/m2 daily ×5, repeated every 3 weeks. The daily dose was reduced to 3000 mg/m2 in patients who had experienced severe myelosuppression with prior chemotherapy. A total of 35 patients were evaluable for response, and 25 of these received two or more courses. Two responses were observed. Toxicity mainly took the form of nausea, vomiting, stomatitis, dizziness, ataxia, and fatigue. Mild leukopenia was frequent (43%). Nadir counts 9/l leukocytes or 50×109/l platelets were seen in 7% and 2% of the courses respectively. Doxifluridine has no useful activity against malignant melanoma.

AB - Forty-two patients with malignant melanoma were treated with doxifluridine, 4000 mg/m2 daily ×5, repeated every 3 weeks. The daily dose was reduced to 3000 mg/m2 in patients who had experienced severe myelosuppression with prior chemotherapy. A total of 35 patients were evaluable for response, and 25 of these received two or more courses. Two responses were observed. Toxicity mainly took the form of nausea, vomiting, stomatitis, dizziness, ataxia, and fatigue. Mild leukopenia was frequent (43%). Nadir counts 9/l leukocytes or 50×109/l platelets were seen in 7% and 2% of the courses respectively. Doxifluridine has no useful activity against malignant melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0022645414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022645414&partnerID=8YFLogxK

U2 - 10.1007/BF00255292

DO - 10.1007/BF00255292

M3 - Article

C2 - 2933177

AN - SCOPUS:0022645414

VL - 16

SP - 78

EP - 79

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -